Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy

Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical trials in patients with advanced ALK- or ROS1-rearrangement NSCLC ind...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Woo Kyung Ryu, Hyungkeun Cha, Mi Hwa Park, Jung Soo Kim, Jeong-Seok Choi, Lucia Kim, Kyung-Hee Lee, Hae-Seong Nam
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-10-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	interstitial lung disease (ILD) ALK (anaplastic lymphoma kinase) ROS1 tyrosine kinase inhibitor (TKI) crizotinib
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2022.900966/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!